Treatment-Resistant Depression
40
10
11
15
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
4 terminated out of 40 trials
78.9%
-7.6% vs benchmark
10%
4 trials in Phase 3/4
47%
7 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (40)
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
NRX-101 Expanded Access
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
Does Psilocybin Require Psychedelic Effects to Treat Depression?
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression
Stereotactic Radiotherapy Treatment for Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression
Olfactory and Brain Stimulations in Treatment-resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
Physical Activity Program for TRD
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression